Bernice Kwong, MD, clinical professor of dermatology, Stanford University, explains what dermatological considerations should be made for patients with leukemia and lymphoma.
Because patients with leukemia and lymphoma are immunocompromised, dermatologists need to look out for more infections and easily compromised skin integrity, explained Bernice Kwong, MD, clinical professor of dermatology, Stanford University.
Transcript
What dermatological considerations should be made regarding the management of patients with leukemia and lymphoma?
For leukemia and lymphoma, the patients are so immunocompromised from their disease already, it's a whole different flavor than our solid organ cancer patients who also have a lot of health issues of the same type. A patient with leukemia and lymphoma, by virtue of their disease, is probably immunocompromised already. When we add treatments onto that, we're going to be looking out for more infections. More infections are going to happen and their skin integrity is probably going to be more easily compromised.
Trying to acknowledge and balance all those things that can be contributing to poor skin healing or toxicity in the skin is really important just to know that their disease itself will manifest in a way that could cause skin problems already. Then, to compound treatments on top of that, we just have to be on a lookout for how even the toxicities from chemotherapies or anticancer agents that we have understood well in solid tumor patients are going to cause skin toxicity and a different flavor for our leukemia and lymphoma patients. Looking at the hosts and acknowledging that they are unique and different too, so that we can look at their skin from that lens, is important.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More